Loading...
Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality
Podszywałow-Bartnicka, Paulina Piwocka, Katarzyna Skorski, Tomasz
Podszywałow-Bartnicka, Paulina
Piwocka, Katarzyna
Skorski, Tomasz
Citations
Altmetric:
Genre
Journal article
Date
2022-11-24
Advisor
Committee member
Department
Cancer and Cellular Biology
Microbiology, Immunology and Inflammation
Microbiology, Immunology and Inflammation
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.3390/cancers14235795
Abstract
The advanced development of synthetic lethality has opened the doors for specific anti-cancer medications of personalized medicine and efficient therapies against cancers. One of the most popular approaches being investigated is targeting DNA repair pathways as the implementation of the PARP inhibitor (PARPi) into individual or combinational therapeutic schemes. Such treatment has been effectively employed against homologous recombination-defective solid tumors as well as hematopoietic malignancies. However, the resistance to PARPi has been observed in both preclinical research and clinical treatment. Therefore, elucidating the mechanisms responsible for the resistance to PARPi is pivotal for the further success of this intervention. Apart from mechanisms of acquired resistance, the bone marrow microenvironment provides a pre-existing mechanism to induce the inefficiency of PARPi in leukemic cells. Here, we describe the pre-existing and acquired mechanisms of the resistance to PARPi-induced synthetic lethality. We also discuss the potential rationales for developing effective therapies to prevent/repress the PARPi resistance in cancer cells.
Description
Citation
Le, B.V.; Podszywałow-Bartnicka, P.; Piwocka, K.; Skorski, T. Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality. Cancers 2022, 14, 5795. https://doi.org/10.3390/cancers14235795
Citation to related work
MDPI
Has part
Cancers, Vol. 14, Iss. 23
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu